Persistent free cash flow deficits, reaching $10.9 million in 2026Q1, highlight a reliance on external capital markets to sustain operations in the absence of commercial revenue.
| Cash from Operations | -29.1M | -25.01M | -10.84M | -13.7M | -14.84M | -7.66M | -45.9M |
| Operating CF Margin % | - | - | - | - | -57.29% | -24.38% | -156.52% |
| Operating CF Growth % | -290.85% | -130.68% | 20.89% | 7.66% | -93.73% | - | - |
| Net Income | -49.3M | -41.72M | -17.43M | 18.69M | -27.55M | -45.74M | -37.23M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 2.37M | 2.13M |
| Stock-Based Compensation | 2.57M | 6.4M | 830K | 603K | 427K | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 164K |
| Other Non-Cash Items | 7.6M | 6.49M | 5.96M | -29.85M | 10.66M | 5.18M | 5.42M |
| Working Capital Changes | 4.38M | 3.82M | -193K | -3.15M | 1.62M | 30.52M | -16.38M |
| Change in Receivables | 2.13M | 2.49M | -1.98M | 0 | 0 | -1.81M | 5.34M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 987K | 1.26M | 2.24M | -2.25M | 1.98M | 7.05M | -4.35M |
| Cash from Investing | -55.44M | 0 | 0 | 0 | 0 | -949K | 39.21M |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | -949K | -2.73M |
| CapEx % of Revenue | - | - | - | - | - | 3.02% | 9.3% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 215.27M | -660K | 87.09M | 5M | 9.57M | 59.13M | 10.12M |
| Debt Issued (Net) | 0 | 0 | 78.43M | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 231.65M | 763K | 0 | 0 | 9.53M | 59.13M | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -16.38M | -1.42M | 8.65M | 5M | 34K | 0 | 0 |
| Net Change in Cash | 130.77M | -25.62M | 76.25M | -8.7M | -5.27M | 47.33M | 8.18M |
| Free Cash Flow | -29.1M | -25.01M | -10.84M | -13.7M | -14.84M | -8.61M | -48.62M |
| FCF Margin % | - | - | - | - | -57.29% | -27.4% | -165.82% |
| FCF Growth % | -95.76% | -130.68% | 20.89% | 7.66% | -72.38% | - | - |
| FCF per Share | -2.22 | -2.22 | -4.87 | -10.81 | -15.95 | -10.67 | -71.40 |
| FCF Conversion (FCF/Net Income) | 0.59x | 0.60x | 0.62x | -0.73x | 0.45x | 0.17x | 1.23x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Clinical trial funding dependency
As reported in recent financial statements, PVLA's operating cash flow of -$10.9 million in 2026Q1 relative to a net loss of -$15.8 million suggests a persistent disconnect between accounting losses and actual cash consumption, driven primarily by the company's ongoing clinical-stage development requirements.
The variance between net income and operating cash flow indicates that non-cash items and working capital adjustments are currently insufficient to offset the heavy cash burn required for clinical operations. Investors should monitor this gap, as it highlights the company's reliance on external financing to bridge the shortfall between accounting losses and operational liquidity needs.
Based on the provided quarterly data, PVLA's free cash flow has remained consistently negative, reaching -$10.9 million in 2026Q1, which underscores the company's status as a pre-revenue entity entirely dependent on capital markets to sustain its research and development trajectory.
The lack of positive free cash flow is an expected characteristic of a clinical-stage biotech, yet the trend of deepening outflows suggests that the cost of advancing the QTORIN program is accelerating. This trajectory implies that the company's runway is being consumed at an increasing rate, necessitating careful scrutiny of future capital allocation decisions.
According to historical cash flow records, working capital changes have been highly erratic, swinging from a -$14.3 million outflow in 2023Q4 to a $3.8 million inflow in 2025Q4, reflecting the lumpy nature of clinical trial milestone payments and vendor management.
These fluctuations suggest that the company's cash position is sensitive to the timing of contractual obligations with clinical research organizations. Analysts should interpret these swings as evidence of the operational complexity inherent in managing late-stage trials rather than a reflection of underlying business efficiency.
As indicated by recent SEC filings, the company has begun utilizing stock-based compensation, with $1.1 million recorded in 2025Q4, which serves to preserve cash but introduces potential future dilution that investors must account for when evaluating the true cost of operations.
While SBC helps mitigate immediate cash outflows, it effectively shifts the burden of funding clinical development onto shareholders through equity dilution. This practice warrants further investigation to determine if the current compensation structure aligns management incentives with the long-term goal of achieving a sustainable commercial launch.
Quick answers to the most common questions about buying PVLA stock.
Palvella Therapeutics, Inc. (PVLA) generated $-25.0M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Palvella Therapeutics, Inc. (PVLA) reported negative free cash flow of $25.0M in 2025, indicating capital requirements exceeded cash from operations.
Palvella Therapeutics, Inc. (PVLA) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.